These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682 [TBL] [Abstract][Full Text] [Related]
6. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763 [TBL] [Abstract][Full Text] [Related]
7. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening. Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937 [TBL] [Abstract][Full Text] [Related]
9. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors. Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674 [TBL] [Abstract][Full Text] [Related]
10. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559 [TBL] [Abstract][Full Text] [Related]
11. Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. de Almeida Nagata DE; Chiang EY; Jhunjhunwala S; Caplazi P; Arumugam V; Modrusan Z; Chan E; Merchant M; Jin L; Arnott D; Romero FA; Magnuson S; Gascoigne KE; Grogan JL Cell Rep; 2019 Apr; 27(1):269-281.e4. PubMed ID: 30943407 [TBL] [Abstract][Full Text] [Related]
12. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines. Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771 [TBL] [Abstract][Full Text] [Related]
13. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866 [TBL] [Abstract][Full Text] [Related]
14. Development of Dimethylisoxazole-Attached Imidazo[1,2- Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011 [TBL] [Abstract][Full Text] [Related]
15. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation. Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323 [TBL] [Abstract][Full Text] [Related]
17. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957 [TBL] [Abstract][Full Text] [Related]
18. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Ryan KR; Giles F; Morgan GJ Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714 [TBL] [Abstract][Full Text] [Related]
20. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]